An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * During dose escalation, subjects with advanced solid tumors that have progressed following at least one standard regimen * During cohort expansion, subjects with advanced cancer that either have received at least one prior therapy or are treatment naive, depending on the specified tumor type * Subjects must have measurable disease * Subject must consent to provide previously collected tumor tissue and a tumor biopsy during screening. * At least 4 weeks since any previous treatment for cancer * Must be able to swallow pills or capsules * Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1 Exclusion Criteria: * Active or chronic autoimmune diseases * Uncontrolled or significant cardiovascular disease * History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS) * Chronic hepatitis: Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except for subjects with hepatocellular carcinoma) * Active central nervous system (CNS) metastases and CNS metastases as the only sites of disease * Active infection Other protocol defined inclusion/exclusion criteria could apply